Genitourinary Cancers

10 protocols meet the specified criteria.

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • A211901

    Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • EAY191-N5

    A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

  • GRAIL-MA-002

    REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

  • NRG-CC014

    Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

  • NRG-GU013

    THE PHASE III HIGH FIVE TRIAL FIVE FRACTION RADIATION FOR HIGH-RISK PROSTATE CANCER

  • NRG-GU014

    Randomized Phase II Trial of Pembrolizumab and Radiation vs Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC)

  • S1802

    Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

  • S2312

    A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature